Magi Astrology--Financial Astrology

FINANCIAL ASTROLOGY

First Trade Date for Sepracor Inc.

Company Name	First Trade Date (yyyy-mm-dd)
Sepracor Inc.	1991-09-20

Company Name	Symbol
Sepracor Inc.	SEPR
History and Business of Company (this information may include date of incorporation)
Sepracor Inc. (SEPR) is a pharmaceutical company focused on the cost-effective development of potentially safer, purer and more effective drugs known as improved chemical entities (ICEs). ICEs are patented, single-isomer or active-metabolite versions of widely prescribed drugs presently marketed by other pharmaceutical companies. The company selects for development compounds with the potential to offer improvements over existing therapies with respect to efficacy, side-effect profile or both. SEPR develops and markets these drugs by leveraging its expertise in conducting preclinical and clinical trials and seeking regulatory approvals for new drugs. SEPR's drug development program has yielded an extensive portfolio of pharmaceuticals and drug candidates intended to treat a broad range of indications. SEPR is concentrating its product development efforts in three major therapeutic areas: respiratory, urological and central nervous system disorders. Certain of these candidates have been, and are being developed at lower cost and in less time than the new chemical entities that characterize traditional drug development. The company believes that the probability of the United States Food and Drug Administration (FDA) approval of its ICE drug candidates is increased because the parent drugs have previously been approved. The company's strategy for commercializing its ICE pharmaceuticals includes licensing and co-promotion collaborations with major pharmaceutical companies and direct marketing through one or more specialty sales forces. In May 1999, SEPR launched Xopenex, an improved version of generic levalbuterol (a short- acting bronchodilator treatment for asthma sold under the Ventolin and Proventil names), under a co-promotion agreement with Abbott Laboratories. In October 1999, the company obtained a license to Rhoe Poulenc Rorer clinical and post-marketing surveillance data on Zopiclone. Other licensing agreements are in place with major drug manufacturers such as Eli Lilly for Fluoxetine, marketed as Prozac by Eli Lilly; Norcisapride, indicated for the treatment of patients with nocturnal heartburn due to gastroesophageal reflux disease; Schering-Plough, for the right to market Desloratadine, marketed by Schering as the antihistamine Claritin; and with Hoechst Marion Roussel for Fexofenadine, an improved version of the antihistamine Seldane. INCORPORATED in Delaware Jan. 27, 1984. OFFICE- 111 Locke Drive, Marlborough, MA, USA 01757 (Tel.: 508-481-6700). Fax - 508-481- 7683. WEBSITE-http://www.sepracor.com.

IMPORTANT DISCLAIMER: By reading any of the material on this website you agree to our DISCLAIMER: The Magi Society, Magi Astrologers Worldwide Corporation make no claims whatsoever concerning the validity of the information provided herein, and will not be held liable for any use thereof. No information or opinion expressed here is a solicitation to buy or sell securities, bonds, real estate, commodities, options, futures or any financial instruments whatsoever.